INTRODUCTION: Development of agonist positron emission tomography (PET) radioligands for the 5-HT neurotransmitter system is an important target to enable the understanding of human 5-HT function in vivo. [(11)C]CUMI-101, proposed as the first 5-HT(1A) receptor agonist PET ligand, has been reported to behave as a potent 5-HT(1A) agonist in a cellular system stably expressing human recombinant 5-HT(1A) receptors. In this study, we investigate the agonist properties of CUMI-101 in rat brain tissue. METHODS: [(35)S]-GTPγS binding studies were used to determine receptor function in HEK (human embryonic kidney) 293 cells transfected with human recombinant 5-HT(1A) receptors and in rat cortex and rat hippocampal tissue, following administration of CUMI-101 and standard 5-HT1A antagonists (5-HT, 5-CT and 8-OH-DPAT). RESULTS: CUMI-101 behaved as an agonist at human recombinant 5-HT(1A) receptors (pEC(50) 9.2). However, CUMI-101 did not show agonist activity in either rat cortex or hippocampus at concentrations up to 10 μM. In these tissues, CUMI-behaved as an antagonist with pK(B)s of 9.2 and 9.3, respectively. CONCLUSIONS: Our studies demonstrate that as opposed to its behavior in human recombinant system, in rat brain tissue CUMI-101 behaves as a potent 5-HT(1A) receptor antagonist.
INTRODUCTION: Development of agonist positron emission tomography (PET) radioligands for the 5-HT neurotransmitter system is an important target to enable the understanding of human 5-HT function in vivo. [(11)C]CUMI-101, proposed as the first 5-HT(1A) receptor agonist PET ligand, has been reported to behave as a potent 5-HT(1A) agonist in a cellular system stably expressing human recombinant 5-HT(1A) receptors. In this study, we investigate the agonist properties of CUMI-101 in rat brain tissue. METHODS: [(35)S]-GTPγS binding studies were used to determine receptor function in HEK (humanembryonic kidney) 293 cells transfected with human recombinant 5-HT(1A) receptors and in rat cortex and rat hippocampal tissue, following administration of CUMI-101 and standard 5-HT1A antagonists (5-HT, 5-CT and 8-OH-DPAT). RESULTS:CUMI-101 behaved as an agonist at human recombinant 5-HT(1A) receptors (pEC(50) 9.2). However, CUMI-101 did not show agonist activity in either rat cortex or hippocampus at concentrations up to 10 μM. In these tissues, CUMI-behaved as an antagonist with pK(B)s of 9.2 and 9.3, respectively. CONCLUSIONS: Our studies demonstrate that as opposed to its behavior in human recombinant system, in rat brain tissue CUMI-101 behaves as a potent 5-HT(1A) receptor antagonist.
Authors: Stal Saurav Shrestha; Jeih-San Liow; Shuiyu Lu; Kimberly Jenko; Robert L Gladding; Per Svenningsson; Cheryl L Morse; Sami S Zoghbi; Victor W Pike; Robert B Innis Journal: J Nucl Med Date: 2014-01 Impact factor: 10.057
Authors: J S Dileep Kumar; Ramin V Parsey; Suham A Kassir; Vattoly J Majo; Matthew S Milak; Jaya Prabhakaran; Norman R Simpson; Mark D Underwood; J John Mann; Victoria Arango Journal: Brain Res Date: 2013-02-27 Impact factor: 3.252
Authors: J S Dileep Kumar; Mark D Underwood; Norman R Simpson; Suham A Kassir; Jaya Prabhakaran; Vattoly J Majo; Mihran J Bakalian; Ramin V Parsey; J John Mann; Victoria Arango Journal: ACS Med Chem Lett Date: 2016-03-13 Impact factor: 4.345
Authors: Sjoerd J Finnema; Mika Scheinin; Mohammed Shahid; Jussi Lehto; Edilio Borroni; Benny Bang-Andersen; Jukka Sallinen; Erik Wong; Lars Farde; Christer Halldin; Sarah Grimwood Journal: Psychopharmacology (Berl) Date: 2015-04-30 Impact factor: 4.530
Authors: Sudhakar Selvaraj; Chris Walker; Danilo Arnone; Bo Cao; Paul Faulkner; Philip J Cowen; Jonathan P Roiser; Oliver Howes Journal: Neuropsychopharmacology Date: 2017-08-04 Impact factor: 7.853
Authors: Vladimir Shalgunov; Aren van Waarde; Jan Booij; Martin C Michel; Rudi A J O Dierckx; Philip H Elsinga Journal: Med Res Rev Date: 2018-11-18 Impact factor: 12.944